This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications. This protocol will allow access to cord blood units that are unlicensed.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

Participants in this study will be asked to give a small blood sample during a routine clinic check-up. Researchers will be looking at blood components and compare with expected venetoclax concentrations. The overall goal is to be able to use specific blood components ("biomarkers") to better optimize venetoclax doses for CLL patients.

To compare the prevalence, severity, and timing of chronic health conditions (CHC) in a cohort of patients with DS-AL (Down Syndrome Acute Leukemia) with age-comparable DS individuals that have no cancer history. Our secondary objectives will compare NP (Neuro-Psychological) and health-related quality of life outcomes in survivors of DS-AL compared with age-comparable DS individuals with no cancer history, and will identify risk determinants of CHC and NP late effects among survivors of DS-AL.

we will be conducting 60-minute interviews with young adults to hear about social connections (in person and online) and cancer support on social media

Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.

To conduct focus groups and semi-structured interviews of parents with cancer - and their co-parents - about their experiences communicating with their minor children about cancer to inform the development of a communication intervention support tool.

The purpose of this study is to collect evidence for or against the addition of olanzapine to standard nausea/vomiting prophylaxis in children receiving cyclophosphamide-based Bone Marrow Transplant conditioning. Its findings will be generalizable to children receiving other types of chemotherapy that have the potential to increase nausea/vomiting.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

Collecting data on chronic GVHD instances